Pages that link to "Q424760"
Jump to navigation
Jump to search
The following pages link to dutasteride (Q424760):
Displayed 50 items.
- baldness (Q181391) (← links)
- prostatic hypertrophy (Q506659) (← links)
- prostate disease (Q18556445) (← links)
- The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men (Q24658075) (← links)
- Fixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasia (Q26770425) (← links)
- Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review (Q28069186) (← links)
- The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study (Q28261198) (← links)
- The effect of finasteride and dutasteride on the growth of WPE1-NA22 prostate cancer xenografts in nude mice (Q28478721) (← links)
- Preventive and therapeutic efficacy of finasteride and dutasteride in TRAMP mice (Q28534518) (← links)
- Controlled release of dutasteride from biodegradable microspheres: in vitro and in vivo studies (Q28542853) (← links)
- Effect of dutasteride on the risk of prostate cancer (Q30010961) (← links)
- Cost effectiveness comparison of dutasteride and finasteride in patients with benign prostatic hyperplasia--The Markov model based on data from Montenegro (Q31056653) (← links)
- Dutasteride: a review of current data on a novel dual inhibitor of 5alpha reductase. (Q31061631) (← links)
- The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the Comb (Q33384745) (← links)
- Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial (Q33411942) (← links)
- Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study. (Q33582528) (← links)
- Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy (Q33775549) (← links)
- The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (Com (Q33829176) (← links)
- Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia (Q33961645) (← links)
- Alcohol intake increases high-grade prostate cancer risk among men taking dutasteride in the REDUCE trial (Q34022156) (← links)
- The different reduction rate of prostate-specific antigen in dutasteride and finasteride (Q34239009) (← links)
- Dutasteride for the treatment of prostate-related conditions (Q34252953) (← links)
- Dutasteride reduces alcohol's sedative effects in men in a human laboratory setting and reduces drinking in the natural environment (Q34273786) (← links)
- Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor (Q34318703) (← links)
- Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer (Q34341146) (← links)
- Dutasteride for the treatment of benign prostatic hyperplasia (Q34349726) (← links)
- Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year r (Q34377799) (← links)
- The REDUCE metagram: a comprehensive prediction tool for determining the utility of dutasteride chemoprevention in men at risk for prostate cancer (Q34453917) (← links)
- A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer (Q34479486) (← links)
- Randomized non-inferiority trial of Bicalutamide and Dutasteride versus LHRH agonists for prostate volume reduction prior to I-125 permanent implant brachytherapy for prostate cancer (Q34506507) (← links)
- Discovery and clinical development of dutasteride, a potent dual 5alpha-reductase inhibitor (Q34529588) (← links)
- The AVOCAT study: Bicalutamide monotherapy versus combined bicalutamide plus dutasteride therapy for patients with locally advanced or metastatic carcinoma of the prostate-a long-term follow-up comparison and quality of life analysis. (Q34531624) (← links)
- Safety and Tolerability of the Dual 5-Alpha Reductase Inhibitor Dutasteride in the Treatment of Androgenetic Alopecia (Q34536368) (← links)
- Dutasteride plus tamsulosin fixed-dose combination first-line therapy versus tamsulosin monotherapy in the treatment of benign prostatic hyperplasia: a budget impact analysis in the Greek healthcare setting (Q34539001) (← links)
- Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy (Q34547874) (← links)
- The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer--results from a 4-month pre-radical prostatectomy study (Q34559834) (← links)
- The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride (Q34572614) (← links)
- Combined dutasteride and tamsulosin (Q34633830) (← links)
- Experience with the combination of dutasteride and tamsulosin in the long-term management of benign prostatic hyperplasia (Q34643351) (← links)
- Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. (Q34666168) (← links)
- Reliable and sensitive determination of dutasteride in human plasma by liquid chromatography-tandem mass spectrometry (Q34699466) (← links)
- Oral testosterone with and without concomitant inhibition of 5α-reductase by dutasteride in hypogonadal men for 28 days (Q34710289) (← links)
- Dutasteride: a review of its use in the management of prostate disorders (Q34758160) (← links)
- Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design. (Q35005972) (← links)
- Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer (Q35011129) (← links)
- Effects of short-term dutasteride and Serenoa repens on perioperative bleeding and microvessel density in patients undergoing transurethral resection of the prostate (Q35013421) (← links)
- Decision analysis of dutasteride use for patients with negative prostate biopsy (Q35020507) (← links)
- Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis (Q35087049) (← links)
- Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia (Q35157640) (← links)
- Effect of dutasteride on microvessel density in benign prostatic hyperplasia (Q35166347) (← links)